Three month treatment of reactive arthritis with azithromycin: A EULAR double blind, placebo controlled study

Annals of the Rheumatic Diseases

Volumn 63, Issue 9, 2004, Pages 1113-1119

  Kvien, T K ^a   Gaston, J S H ^b   Bardin, T ^c   Butrimiene, I ^d   Dijkmans, B A C ^e   Leirisalo Repo, M ^f   Solakov, P ^g   Altwegg, M ^h   Mowinckel, P ^a   Plan, P A ⁱ   Vischer, T ^j  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c HÔPITAL LARIBOISIÈRE   (France)

^d VILNIUS UNIVERSITY   (Lithuania)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF HELSINKI   (Finland)

^g University Clinic of Rheumatology   (Bulgaria)

^h UNIVERSITY OF ZURICH   (Switzerland)

ⁱ University of Zurich ^*  (Switzerland)

^j GENEVA UNIVERSITY HOSPITALS   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; C REACTIVE PROTEIN; HLA B27 ANTIGEN;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; CHLAMYDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EDEMA; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEEL PAIN; HUMAN; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REACTIVE ARTHRITIS; RESPIRATORY TRACT DISEASE; SINGLE DRUG DOSE; SKIN DISEASE; STOMATITIS; SYMPTOM; UROGENITAL TRACT DISEASE;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ARTHRITIS, REACTIVE; AZITHROMYCIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 4344624609     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.010710     Document Type: Article

References (48)

1. Keat A. Reiter's syndrome and reactive arthritis in perspective. N Engl J Med 1983;309:1606-15.
2. Kvien TK, Glennas A, Melby K, Granfors K, Andrup O, Karstensen B, et al. Reactive arthritis: incidence, triggering agents and clinical presentation. J Rheumatol 1994;21:115-22.
3. Granfors K, Viljanen M, Tiilikainen A, Toivanen A. Persistence of IgM, IgG, and IgA antibodies to Yersinia in yersinia arthritis. J Infect Dis 1980;141:424-9.
4. Granfors K, Taivanen A. IgA-anti-yersinia antibodies in yersinia triggered reactive arthritis. Ann Rheum Dis 1986;45:561-5.
5. Gaston JS, Life PF, Granfors K, Merilahti-Palo R, Bailey L, Consalvey S, et al. Synovial T lymphocyte recognition of organisms that trigger reactive arthritis. Clin Exp Immunol 1989;76:348-53.
6. Sieper J, Braun J, Wu P, Kingsley G. T cells are responsible for the enhanced synovial cellular immune response to triggering antigen in reactive arthritis. Clin Exp Immunol 1993;91:96-102.
7. Hermann E, Yu DT, Meyer zum Buschenfelde KH, Fleischer B. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 1993;342:646-50.
8. Gerard HC, Branigan PJ, Schumacher HR Jr, Hudson AP. Synovial Chlamydia trachomatis in patients with reactive arthritis/Reiter's syndrome are viable but show aberrant gene expression. J Rheumatol 1998;25:734-42.
9. Freise J, Gerard HC, Bunke T, Whittum-Hudson JA, Zeidler H, Kohler L, et al. Optimised sample DNA preparation for detection of Chlamydia trachomatis in synovial tissue by polymerase chain reaction and ligase chain reaction. Ann Rheum Dis 2001;60:140-5.
10. Schnarr S, Putschky N, Jendro MC, Zeidler H, Hammer M, Kuipers JG, et al. Chlamydia and Borrelia DNA in synovial fluid of patients with early undifferentiated oligoarthritis: results of a prospective study. Arthritis Rheum 2001;44:2679-85.
11. Keat A, Thomas B, Dixey J, Osborn M, Sonnex C, Taylor-Robinson D. Chlamydia trachomatis and reactive arthritis: the missing link. Lancet 1987;i:72-4.
12. Granfors K, Jalkanen S, von Essen R, Lahesmaa-Rantala R, Isomaki O, Pekkola-Heino K, et al. Yersinia antigens in synoviol-fluid cells from patients with reactive arthritis. N Engl J Med 1989;320:216-21.
13. Granfors K, Jalkanen S, Lindberg AA, Maki-Ikola O, von Essen R, Lahesmaa-Rantala R, et al. Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis. Lancet 1990;335:685-8.
14. Granfors K, Jalkanen S, Toivanen P, Koski J, Lindberg AA. Bacterial lipopolysaccharide in synovial fluid cells in Shigella triggered reactive arthritis. J Rheumatol 1992;19:500.
15. Nikkari S, Merilahti-Palo R, Saaria R, Soderstram KO, Granfors K, Skurnik M, et al. Yersinia-triggered reactive arthritis. Use of polymerase chain reaction and immunocytochemical staining in the detection of bacterial components from synovial specimens. Arthritis Rheum 1992;35:682-7.
16. Nikkari S, Rantakokko K, Ekman P, Mottonen T, Leirisalo-Repo M, Virtala M, et al. Salmonella-triggered reactive arthritis: use of polymerase chain reaction, immunocytochemical staining, and gas chromatography-mass spectrometry in the detection of bacterial components from synovial fluid. Arthritis Rheum 1999;42:84-9.
17. Gaston JS, Cox C, Granfors K. Clinical and experimental evidence for persistent Yersinia infection in reactive arthritis. Arthritis Rheum 1999;42:2239-42.
18. Lauhio A, Leirisalo-Repo M, Lahdevirta J, Saikku P, Repo H. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum 1991:34:6-14.
19. Neu HC. Clinical microbiology of azithromycin. Am J Med 1991;91:12-18S.
20. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med 1991;91:5-11S.
21. Lauharanta J, Saarinen K, Mustonen MT, Happonen HP. Single-dose oral azithromycin versus seven-day doxycycline in the treatment of non-gonococcal urethritis in males. J Antimicrob Chemother 1993;31(suppl E):177-83.
22. Lister PJ, Balechandran T, Ridgway GL, Robinson AJ. Comparison of azithromycin and doxycycline in the treatment of non-gonococcal urethritis in men. J Antimicrob Chemother 1993;31(suppl E):185-92.
23. Toivanen A, Yli-Kerttula T, Luukkainen R, Merilahti-Palo R, Granfors K, Seppala J. Effect of antimicrobial treatment on chronic reactive arthritis. Clin Exp Rheumatol 1993;11:301-7.
24. Wakefield D, McCluskey P, Verma M, Aziz K, Gatus B, Carr G. Ciprofloxacin treatment does not influence course or relapse rate of reactive arthritis and anterior uveitis. Arthritis Rheum 1999;42:1894-7.
25. Sieper J, Fendler C, Laitko S, Sorensen H, Gripenberg-Lerche C, Hiepe F, et al. No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study. Arthritis Rheum 1999;42:1386-90.
26. Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, Mottonen T, Hakola M, Korpela M, et al. Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. Ann Rheum Dis 2000;59:565-70.
27. Hoogkamp Korstonje JA, de Koning J, Heesemann J. Persistence of Yersinia enterocolitica in man. Infection 1988;16:81-5.
28. Hoogkamp-Korstanje JA, Moesker H, Bruyn GA. Ciprofloxacin v placebo for treatment of Yersinia enterocolitica triggered reactive arthritis. Ann Rheum Dis 2000;59:914-17.
29. Bardin T, Enel C, Cornelis F, Salski C, Jorgensen C, Ward R, et al. Antibiotic treatment of venereal disease and Reiter's syndrome in a Greenland population. Arthritis Rheum 1992;35:190-4.
30. Hannu T, Mattila L, Siitonen A, Leirisalo-Repo M. Reactive arthritis following an outbreak of Salmonella typhimurium phage type 193 infection. Ann Rheum Dis 2002;61:264-6.
31. Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, Mottonen T, Hakola M, Korpela M, et al. Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis. Ann Rheum Dis 2003;62:880-4.
32. Braun J, Kingsley G, van der Heijde D, Sieper J. On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, Germany, July 3-6, 1999. J Rheumatol 2000;27:2185-92.
33. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
34. Goldenberger D, Kunzli A, Vogt P, Zbinden R, Altwegg M. Molecular diagnosis of bacterial endocarditis by broad-range PCR amplification and direct sequencing. J Clin Microbiol 1997;35:2733-9.
35. Lipowsky C, Altwegg M, Michel BA, Bruhlmann P. Detection of Borrelia burgdorferi by species-specific and broad-range PCR of synovial fluid and synovial tissue of Lyme arthritis patients before and after antibiotic treatment. Clin Exp Rheumatol 2003;21:271-2.
36. Leirisalo M, Skylv G, Kousa M, Voipio-Pulkki LM, Suoranta H, Nissila M, et al. Followup study on patients with Reiter's disease and reactive arthritis, with special reference to HLA-B27. Arthritis Rheum 1982;25:249-59.
37. Ekman P, Kirveskari J, Granfors K. Modification of disease outcome in Salmonella-infected patients by HLA-B27. Arthritis Rheum 2000;43:1527-34.
38. Hammer M, Zeidler H, Klimsa S, Heesemann J. Yersinia enterocolitica in the synovial membrane of patients with Yersinia-induced arthritis. Arthritis Rheum 1990;33:1795-800.
39. Merilahti-Palo R, Soderstrom KO, Lahesmaa-Rantala R, Granfors K, Toivanen A. Bacterial antigens in synovial biopsy specimens in yersinia triggered reactive arthritis. Ann Rheum Dis 1991;50:87-90.
40. Granfors K, Merilahti-Palo R, Luukkainen R, Mottonen T, Lahesmaa R, Probst P, et al. Persistence of Yersinia antigens in peripheral blood cells from patients with Yersinia enterocolitica O:3 infection with or without reactive arthritis. Arthritis Rheum 1998;41:855-62.
41. Kuipers JG, Nietfeld L, Dreses-Werringloer U, Koehler L, Wollenhaupt J, Zeidler H, et al. Optimised sample preparation of synovial fluid for detection of Chlamydia trachomatis DNA by polymerase chain reaction. Ann Rheum Dis 1999;58:103-8.
42. Boyle LH, Goodall JC, Opat SS, Gaston JS. The recognition of HLA-B27 by human CD4(+) T lymphocytes. J Immunol 2001;167:2619-24.
43. Zhang Y, Gripenberg-Lerche C, Soderstrom KO, Toivanen A, Toivanen P. Antibiotic prophylaxis and treatment of reactive arthritis. Lessons from an animal model. Arthritis Rheum 1996;39:1238-43.
44. Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
45. Egsmose C, Hansen TM, Andersen LS, Beier JM, Christensen L, Ejstrup L, et al. Limited effect of sulphasalazine treatment in reactive arthritis. A randomised double blind placebo controlled trial. Ann Rheum Dis 1997;56:32-6.
46. Clegg DO, Reda DJ, Weisman MH, Cush JJ, Vasey FB, Schumacher HR Jr, et al. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2021-7.
47. Brandt J, Haibel H, Reddig J, Sieper J, Braun J. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 2002;29:118-22.
48. Kaipiainen-Seppänen O, Niinisalo H, Korpilähde T, Virolainen J. Treatment of reactive arthritis with infliximab. Scand J Rheumatol 2003;32:122-4.